Dr. Lal PathLabs surged 4.54% to end at Rs 3716, as the scrip resumed its uptrend after a day's pause.
The stock had declined by 4.77% to closed at 3,554.55 on Friday (30 July 2021).
On a year-to-date (YTD) basis, the stock has zoomed 61.05% while the benchmark Sensex has added 10.89% during the same period.
Dr. Lal PathLabs had announced its earnings for the quarter ended 30 June 2021 during market hours on Friday.
The diagnostic services provider reported 370.4% jump in consolidated net profit to Rs 133.7 crore in Q1 FY22 from Rs 28.4 crore in Q1 FY21.
Revenue increased by 128.1% YoY to Rs 606.6 crore during the quarter. As compared with Q4 FY21, the company's net profit and revenues have increased by 57.1% and 40.7%, respectively.
Normalised EBITDA increased by 268.7% to Rs 199 crore in Q1 FY22 from Rs 54 crore in Q1 FY21. Normalised margins were at 32.8% as on 30 June 2021 as against 20.3% as on 30 June 2020.
Profit before tax in Q1 FY22 stood at Rs 179.3 crore, up by 370% from Rs 38.1 crore in Q1 FY21.
Interim dividend of Rs 6 per equity share has been approved by the board of the company.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services. As on 31 March 2021 the company has 231 clinical laboratories, 3,705 patient service centers (PSCs) and 9,247 pickup points (PUPs).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
